LymphedemaV1, PubMed, Curation, bibRecord, 000980

The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.

Identifieur interne : 000980 ( PubMed/Curation ); précédent : 000979; suivant : 000981

The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.

Auteurs : Chao Han [République populaire de Chine] ; Ben Yang [République populaire de Chine] ; Wen-Shu Zuo [République populaire de Chine] ; Gang Zheng [République populaire de Chine] ; Li Yang [République populaire de Chine] ; Mei-Zhu Zheng [République populaire de Chine]

Source :

PloS one [ 1932-6203 ] ; 2016.

RBID : pubmed:26919589

Descripteurs français

KwdFr :
- Agents colorants (administration et posologie), Aisselle, Biopsie de noeud lymphatique sentinelle (effets indésirables), Bras (anatomie et histologie), Femelle, Humains, Injections intradermiques, Lymphadénectomie (), Lymphadénectomie (effets indésirables), Lymphoedème (), Lymphoedème (étiologie), Métastase lymphatique, Noeuds lymphatiques (anatomopathologie), Soins préopératoires, Système lymphatique (anatomie et histologie), Tumeurs du sein (anatomopathologie), Vaisseaux lymphatiques (anatomie et histologie), Études de faisabilité, Études prospectives.
MESH :
- administration et posologie : Agents colorants.
- anatomie et histologie : Bras, Système lymphatique, Vaisseaux lymphatiques.
- anatomopathologie : Noeuds lymphatiques, Tumeurs du sein.
- effets indésirables : Biopsie de noeud lymphatique sentinelle, Lymphadénectomie.
- étiologie : Lymphoedème.
- Aisselle, Femelle, Humains, Injections intradermiques, Lymphadénectomie, Lymphoedème, Métastase lymphatique, Soins préopératoires, Études de faisabilité, Études prospectives.

English descriptors

KwdEn :
- Arm (anatomy & histology), Axilla, Breast Neoplasms (pathology), Coloring Agents (administration & dosage), Feasibility Studies, Female, Humans, Injections, Intradermal, Lymph Node Excision (adverse effects), Lymph Node Excision (methods), Lymph Nodes (pathology), Lymphatic Metastasis, Lymphatic System (anatomy & histology), Lymphatic Vessels (anatomy & histology), Lymphedema (etiology), Lymphedema (prevention & control), Preoperative Care, Prospective Studies, Sentinel Lymph Node Biopsy (adverse effects).
MESH :
- chemical , administration & dosage : Coloring Agents.
- adverse effects : Lymph Node Excision, Sentinel Lymph Node Biopsy.
- anatomy & histology : Arm, Lymphatic System, Lymphatic Vessels.
- etiology : Lymphedema.
- methods : Lymph Node Excision.
- pathology : Breast Neoplasms, Lymph Nodes.
- prevention & control : Lymphedema.
- Axilla, Feasibility Studies, Female, Humans, Injections, Intradermal, Lymphatic Metastasis, Preoperative Care, Prospective Studies.

Abstract

The axillary reverse mapping (ARM) technique has recently been developed to prevent lymphedema by preserving the arm lymphatic drainage during sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) procedures. The objective of this systematic review and meta-analysis was to evaluate the feasibility and oncological safety of ARM.

DOI: 10.1371/journal.pone.0150285
PubMed: 26919589

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000980

Links to Exploration step

pubmed:26919589

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.</title>
<author><name sortKey="Han, Chao" sort="Han, Chao" uniqKey="Han C" first="Chao" last="Han">Chao Han</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Ben" sort="Yang, Ben" uniqKey="Yang B" first="Ben" last="Yang">Ben Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zuo, Wen Shu" sort="Zuo, Wen Shu" uniqKey="Zuo W" first="Wen-Shu" last="Zuo">Wen-Shu Zuo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Gang" sort="Zheng, Gang" uniqKey="Zheng G" first="Gang" last="Zheng">Gang Zheng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Li" sort="Yang, Li" uniqKey="Yang L" first="Li" last="Yang">Li Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Mei Zhu" sort="Zheng, Mei Zhu" uniqKey="Zheng M" first="Mei-Zhu" last="Zheng">Mei-Zhu Zheng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26919589</idno>
<idno type="pmid">26919589</idno>
<idno type="doi">10.1371/journal.pone.0150285</idno>
<idno type="wicri:Area/PubMed/Corpus">000980</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000980</idno>
<idno type="wicri:Area/PubMed/Curation">000980</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000980</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.</title>
<author><name sortKey="Han, Chao" sort="Han, Chao" uniqKey="Han C" first="Chao" last="Han">Chao Han</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Ben" sort="Yang, Ben" uniqKey="Yang B" first="Ben" last="Yang">Ben Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zuo, Wen Shu" sort="Zuo, Wen Shu" uniqKey="Zuo W" first="Wen-Shu" last="Zuo">Wen-Shu Zuo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Gang" sort="Zheng, Gang" uniqKey="Zheng G" first="Gang" last="Zheng">Gang Zheng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Li" sort="Yang, Li" uniqKey="Yang L" first="Li" last="Yang">Li Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Mei Zhu" sort="Zheng, Mei Zhu" uniqKey="Zheng M" first="Mei-Zhu" last="Zheng">Mei-Zhu Zheng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Arm (anatomy & histology)</term>
<term>Axilla</term>
<term>Breast Neoplasms (pathology)</term>
<term>Coloring Agents (administration & dosage)</term>
<term>Feasibility Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intradermal</term>
<term>Lymph Node Excision (adverse effects)</term>
<term>Lymph Node Excision (methods)</term>
<term>Lymph Nodes (pathology)</term>
<term>Lymphatic Metastasis</term>
<term>Lymphatic System (anatomy & histology)</term>
<term>Lymphatic Vessels (anatomy & histology)</term>
<term>Lymphedema (etiology)</term>
<term>Lymphedema (prevention & control)</term>
<term>Preoperative Care</term>
<term>Prospective Studies</term>
<term>Sentinel Lymph Node Biopsy (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents colorants (administration et posologie)</term>
<term>Aisselle</term>
<term>Biopsie de noeud lymphatique sentinelle (effets indésirables)</term>
<term>Bras (anatomie et histologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Injections intradermiques</term>
<term>Lymphadénectomie ()</term>
<term>Lymphadénectomie (effets indésirables)</term>
<term>Lymphoedème ()</term>
<term>Lymphoedème (étiologie)</term>
<term>Métastase lymphatique</term>
<term>Noeuds lymphatiques (anatomopathologie)</term>
<term>Soins préopératoires</term>
<term>Système lymphatique (anatomie et histologie)</term>
<term>Tumeurs du sein (anatomopathologie)</term>
<term>Vaisseaux lymphatiques (anatomie et histologie)</term>
<term>Études de faisabilité</term>
<term>Études prospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Coloring Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents colorants</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymph Node Excision</term>
<term>Sentinel Lymph Node Biopsy</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomie et histologie" xml:lang="fr"><term>Bras</term>
<term>Système lymphatique</term>
<term>Vaisseaux lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Noeuds lymphatiques</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomy & histology" xml:lang="en"><term>Arm</term>
<term>Lymphatic System</term>
<term>Lymphatic Vessels</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Biopsie de noeud lymphatique sentinelle</term>
<term>Lymphadénectomie</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Lymph Node Excision</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term>
<term>Lymph Nodes</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Axilla</term>
<term>Feasibility Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intradermal</term>
<term>Lymphatic Metastasis</term>
<term>Preoperative Care</term>
<term>Prospective Studies</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Aisselle</term>
<term>Femelle</term>
<term>Humains</term>
<term>Injections intradermiques</term>
<term>Lymphadénectomie</term>
<term>Lymphoedème</term>
<term>Métastase lymphatique</term>
<term>Soins préopératoires</term>
<term>Études de faisabilité</term>
<term>Études prospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The axillary reverse mapping (ARM) technique has recently been developed to prevent lymphedema by preserving the arm lymphatic drainage during sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) procedures. The objective of this systematic review and meta-analysis was to evaluate the feasibility and oncological safety of ARM.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26919589</PMID>
<DateCreated><Year>2016</Year>
<Month>02</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>07</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<Issue>2</Issue>
<PubDate><Year>2016</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.</ArticleTitle>
<Pagination><MedlinePgn>e0150285</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0150285</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The axillary reverse mapping (ARM) technique has recently been developed to prevent lymphedema by preserving the arm lymphatic drainage during sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) procedures. The objective of this systematic review and meta-analysis was to evaluate the feasibility and oncological safety of ARM.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We searched Medline, Embase, Web of science, Scopus, and the Cochrane Library for relevant prospective studies. The identification rate of ARM nodes, the crossover rate of SLN-ARM nodes, the proportion of metastatic ARM nodes, and the incidence of complications were pooled into meta-analyses by the random-effects model.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 24 prospective studies were included into meta-analyses, of which 11 studies reported ARM during SLNB, and 18 studies reported ARM during SLNB. The overall identification rate of ARM nodes was 38.2% (95% CI 32.9%-43.8%) during SLNB and 82.8% (78.0%-86.6%) during ALND, respectively. The crossover rate of SLN-ARM nodes was 19.6% (95% CI 14.4%-26.1%). The metastatic rate of ARM nodes was 16.9% (95% CI 14.2%-20.1%). The pooled incidence of lymphedema was 4.1% (95% CI 2.9-5.9%) for patients undergoing ARM procedure.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The ARM procedure was feasible during ALND. Nevertheless, it was restricted by low identification rate of ARM nodes during SLNB. ARM was beneficial for preventing lymphedema. However, this technique should be performed with caution given the possibility of crossover SLN-ARM nodes and metastatic ARM nodes. ARM appeared to be unsuitable for patients with clinically positive breast cancer due to oncological safety concern.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName>
<ForeName>Chao</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>School of Medicine and life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Ben</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zuo</LastName>
<ForeName>Wen-Shu</ForeName>
<Initials>WS</Initials>
<AffiliationInfo><Affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Gang</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Mei-Zhu</ForeName>
<Initials>MZ</Initials>
<AffiliationInfo><Affiliation>Department of Surgery II, Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>02</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2012 Aug;38(8):657-61</RefSource>
<PMID Version="1">22607749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2007 Sep;14(9):2490-6</RefSource>
<PMID Version="1">17549570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2012 May;38(5):390-4</RefSource>
<PMID Version="1">22336143</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Nov 20;27(33):5547-51</RefSource>
<PMID Version="1">19826123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Minerva Ginecol. 2012 Oct;64(5):421-30</RefSource>
<PMID Version="1">23018481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2015 May;209(5):890-5</RefSource>
<PMID Version="1">25796096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Rev Anticancer Ther. 2014 Jul;14(7):771-81</RefSource>
<PMID Version="1">24621187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2009 Oct;198(4):482-7</RefSource>
<PMID Version="1">19800452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2012 Oct;19(11):3410-5</RefSource>
<PMID Version="1">22526910</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2007 Jun;14(6):1890-5</RefSource>
<PMID Version="1">17479341</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 May;14(6):500-15</RefSource>
<PMID Version="1">23540561</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Breast Cancer. 2012 Mar;15(1):91-7</RefSource>
<PMID Version="1">22493634</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Surgery. 2014 Nov;156(5):1261-8</RefSource>
<PMID Version="1">25444319</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2012 Mar;105(3):229-34</RefSource>
<PMID Version="1">21913193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2014 Jul;40(7):818-23</RefSource>
<PMID Version="1">24768416</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Nucl Med. 2014 Oct;39(10):e428-30</RefSource>
<PMID Version="1">24152646</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2009 Sep;16(9):2459-63</RefSource>
<PMID Version="1">19506954</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 2003 Sep 6;327(7414):557-60</RefSource>
<PMID Version="1">12958120</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Surg. 2008 May;206(5):1038-42; discussion 1042-4</RefSource>
<PMID Version="1">18471751</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Compr Canc Netw. 2015 Apr;13(4):448-75</RefSource>
<PMID Version="1">25870381</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62</RefSource>
<PMID Version="1">24114568</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 2011 Dec;137(12):1869-74</RefSource>
<PMID Version="1">21935615</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Dis. 2014 Jan 1;34(4):151-5</RefSource>
<PMID Version="1">24934169</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2015 Aug;15(4):301-6</RefSource>
<PMID Version="1">25776198</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2008 Sep;15(9):2550-5</RefSource>
<PMID Version="1">18618185</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2013 Dec;39(12):1341-5</RefSource>
<PMID Version="1">24113621</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2013 Aug;39(8):880-6</RefSource>
<PMID Version="1">23735162</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2014 Dec;110(7):791-5</RefSource>
<PMID Version="1">25053441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Evid Based Med. 2015 Feb;8(1):2-10</RefSource>
<PMID Version="1">25594108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2012 Jul 1;106(1):89-93</RefSource>
<PMID Version="1">22258666</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2014 May;109(6):612-5</RefSource>
<PMID Version="1">24310418</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2010 Mar 1;101(3):217-21</RefSource>
<PMID Version="1">20063370</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 2001 Oct;54(10):1046-55</RefSource>
<PMID Version="1">11576817</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Surg Oncol. 2012;10:233</RefSource>
<PMID Version="1">23116152</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2015 Jan;41(1):59-63</RefSource>
<PMID Version="1">25468747</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2013 Oct;20(10):3303-7</RefSource>
<PMID Version="1">23975287</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trials. 2013;14:111</RefSource>
<PMID Version="1">23782712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 1997 Sep 13;315(7109):629-34</RefSource>
<PMID Version="1">9310563</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2015 Apr;41(4):442-9</RefSource>
<PMID Version="1">25704555</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 May 1;32(13):1365-83</RefSource>
<PMID Version="1">24663048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Jun 1;116(11):2543-8</RefSource>
<PMID Version="1">20336790</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2014 Jul;21(7):2197-202</RefSource>
<PMID Version="1">24599413</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23</RefSource>
<PMID Version="1">23970019</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2009 Jul 21;6(7):e1000097</RefSource>
<PMID Version="1">19621072</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName>
<QualifierName UI="Q000033" MajorTopicYN="Y">anatomy & histology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001365" MajorTopicYN="Y">Axilla</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004396" MajorTopicYN="Y">Coloring Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008207" MajorTopicYN="Y">Lymphatic Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008208" MajorTopicYN="N">Lymphatic System</DescriptorName>
<QualifierName UI="Q000033" MajorTopicYN="Y">anatomy & histology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName>
<QualifierName UI="Q000033" MajorTopicYN="N">anatomy & histology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D021701" MajorTopicYN="N">Sentinel Lymph Node Biopsy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4769133</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>06</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>02</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>2</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>2</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>7</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26919589</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0150285</ArticleId>
<ArticleId IdType="pii">PONE-D-15-28409</ArticleId>
<ArticleId IdType="pmc">PMC4769133</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000980 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000980 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:26919589
   |texte=   The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:26919589" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.

The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki